Education
About Us
Working with TipRanks
Follow Us
Silence Therapeutics (SLN)
NASDAQ:SLN
Earnings Data
Report Date
May 14, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.15Last Year’s EPS
-0.02Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -30.40%
|Next Earnings Date:May 14, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted positive clinical trial results for zerlasiran and divesiran, revenue growth, and an extended cash runway. However, the termination of the Hansoh Pharma collaboration and the delay of the zerlasiran Phase 3 study due to the need for a partner were significant challenges mentioned.Company Guidance
During the call, Silence Therapeutics provided guidance on several key metrics for their future operations. The company reported $43.3 million in revenues for 2024, an increase from $31.6 million in 2023, largely due to collaboration arrangements. They ended 2024 with $147.3 million in cash, cash equivalents, and short-term investments. Silence announced they would only initiate the Phase 3 outcomes study for zerlasiran, their siRNA for high Lp(a), once a partner is secured, which extends their cash runway into 2027. Additionally, they are prioritizing investment in programs targeting rare conditions, like divesiran for polycythemia vera (PV), which has received orphan drug designation in both the EU and US. The company also plans to commence a Phase 1 study of SLN548 targeting complement factor B in the second half of 2025. Silence transitioned to a U.S. domestic issuer status, moving from IFRS to U.S. GAAP, which resulted in a net loss decrease to $45.3 million in 2024 from $54.2 million in 2023.Positive Results for Zerlasiran Phase 2 Study
The ALPACAR-360 Phase 2 study of zerlasiran in ASCVD patients with high Lp(a) delivered positive results, showing Lp(a) reductions exceeded 90% and were durable. The study was featured in a late-breaker at AHA and published in JAMA.
Divesiran Phase 1 Success and Phase 2 Progress
The SANRECO’s Phase 1 study of divesiran showed positive results, eliminating the need for phlebotomy in all well-controlled patients. Phase 2 study dosing has started, and the European Commission has granted divesiran Orphan Drug Designation for PV.
Revenue Growth
The company recorded $43.3 million in revenues for 2024, an increase of $11.7 million from 2023, largely due to collaboration arrangements utilizing the siRNA platform.
Extension of Cash Runway
By delaying the Phase 3 study of zerlasiran until a partner is secured, the company has extended its projected cash runway into 2027.
---
SLN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SLN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $4.77 | $4.72 | -1.05% |
| Nov 14, 2024 | $15.24 | $13.98 | -8.27% |
| Aug 15, 2024 | $16.26 | $16.77 | +3.14% |
| May 16, 2024 | $22.33 | $22.94 | +2.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Silence Therapeutics (SLN) report earnings?
Silence Therapeutics (SLN) is schdueled to report earning on May 14, 2025, TBA Not Confirmed.
What is Silence Therapeutics (SLN) earnings time?
Silence Therapeutics (SLN) earnings time is at May 14, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SLN EPS forecast?
SLN EPS forecast for the fiscal quarter 2025 (Q1) is -0.15.
---